A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions

ALK PositiveEnsartinibNSCLCNeoadjuvant Therapy

All Listed Sponsors

lead

Harbin Medical University

OTHER